CJC-1295 NO DAC 5 mg

$20.00

    Purity > 99% – View Lab Test

  • PeptideCJC-1295 (no DAC)
  • Amount5 mg per vial
  • FormLyophilized powder
  • Purity≥99% (HPLC COA available)
  • ManufactureGMP-certified facility
  • Storage (dry)Cool, dry place
  • After reconstitution2–8 °C (short-term); ?20 °C for long-term

Out of stock

Description

CJC-1295 (no DAC) — GHRH Analog for Research

CJC-1295 (no DAC) is a synthetic growth-hormone–releasing hormone (GHRH) analog
designed for laboratory use. The “no DAC” designation indicates that this variant does not
contain the drug-affinity complex (DAC) motif, and therefore has a shorter circulating half-life than
DAC-modified versions. In preclinical models, CJC-1295 (no DAC) is used to study pulsatile GH
secretion and downstream IGF-1–linked signaling.

What It Is

  • Class: GHRH (growth hormone–releasing hormone) analog
  • Sequence: 30–amino-acid peptide based on GHRH(1–29) with stabilizing substitutions
  • Variant: “No DAC” — lacks the drug-affinity complex for shorter, more physiological exposure

Proposed Mechanisms (Preclinical)

GHRH Receptor Activation

  • Binds to GHRH receptors on pituitary somatotroph cells.
  • Engages Gs/cAMP/PKA signaling pathways linked to GH release.
  • Supports pulsatile GH secretion patterns in contrast to continuous stimulation models.

Downstream Endocrine Effects

  • Explored for effects on circulating GH and IGF-1 profiles in animal studies.
  • Model-dependent changes in protein synthesis, nitrogen balance, and lean mass parameters.
  • Frequently studied in combination protocols with separate ghrelin mimetics (GHRPs) in research settings.

Selected Research Highlights

  • GH/IGF-1 Profiles: GHRH analogs such as CJC-1295 (no DAC) have been investigated
    for their ability to augment endogenous GH pulses and modulate IGF-1 production in preclinical models.
  • Pulsatile vs. Prolonged Exposure: Shorter-acting, non-DAC variants are often used
    to study the impact of physiologic, transient receptor engagement relative to long-acting depot
    formulations.
  • Body-Composition Models: In animal studies, GHRH analogs have been examined for
    effects on lean mass indices, fat mass, and metabolic markers, typically as exploratory endpoints.
  • Combination Research: Co-administration with separate growth hormone–releasing
    peptides (GHRPs) is a common experimental design to evaluate synergistic stimulation of GH secretion.

Chemical & Handling Information

  • Type: Synthetic peptide, growth hormone–releasing hormone analog (no DAC)
  • Peptide length: 30 amino acids (approximate, sequence-variant dependent)
  • Appearance: White to off-white lyophilized powder

Specifications

  • Peptide: CJC-1295 (no DAC)
  • Amount: 10 mg per vial
  • Form: Lyophilized powder
  • Purity: ?99% (HPLC); COA per lot available
  • Packaging: Sealed vials suitable for standard laboratory handling

Storage & Stability

  • Store lyophilized vials in a cool, dry place, protected from light.
  • For extended stability, keep vials refrigerated or frozen as per laboratory SOPs.
  • After reconstitution, store at 2–8 °C for short-term use.
  • For long-term storage, aliquot and freeze at ?20 °C or below; avoid repeated freeze–thaw cycles.

Reviews

There are no reviews yet.

Be the first to review “CJC-1295 NO DAC 5 mg”

Your email address will not be published. Required fields are marked *